NO20001238L - Monoklonalt antistoff som induserer apoptose - Google Patents

Monoklonalt antistoff som induserer apoptose

Info

Publication number
NO20001238L
NO20001238L NO20001238A NO20001238A NO20001238L NO 20001238 L NO20001238 L NO 20001238L NO 20001238 A NO20001238 A NO 20001238A NO 20001238 A NO20001238 A NO 20001238A NO 20001238 L NO20001238 L NO 20001238L
Authority
NO
Norway
Prior art keywords
antibody
monoclonal antibody
associated proteins
human integrin
apoptosis
Prior art date
Application number
NO20001238A
Other languages
English (en)
Norwegian (no)
Other versions
NO20001238D0 (no
Inventor
Naoshi Fukushima
Shinsuke Uno
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of NO20001238D0 publication Critical patent/NO20001238D0/no
Publication of NO20001238L publication Critical patent/NO20001238L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NO20001238A 1997-09-11 2000-03-09 Monoklonalt antistoff som induserer apoptose NO20001238L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP26485397 1997-09-11
PCT/JP1998/004118 WO1999012973A1 (fr) 1997-09-11 1998-09-11 Anticorps monoclonal induisant l'apoptose

Publications (2)

Publication Number Publication Date
NO20001238D0 NO20001238D0 (no) 2000-03-09
NO20001238L true NO20001238L (no) 2000-05-11

Family

ID=17409137

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20001238A NO20001238L (no) 1997-09-11 2000-03-09 Monoklonalt antistoff som induserer apoptose

Country Status (14)

Country Link
US (1) US20030157100A1 (fr)
EP (1) EP1035132B1 (fr)
KR (2) KR20040106585A (fr)
CN (1) CN1198845C (fr)
AT (1) ATE395362T1 (fr)
AU (1) AU740225B2 (fr)
CA (1) CA2303072A1 (fr)
DE (1) DE69839492D1 (fr)
HU (1) HUP0003513A3 (fr)
NO (1) NO20001238L (fr)
PL (1) PL339265A1 (fr)
RU (1) RU2212413C2 (fr)
SK (1) SK3232000A3 (fr)
WO (1) WO1999012973A1 (fr)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0721015B1 (fr) * 1993-09-03 2004-10-27 Chugai Seiyaku Kabushiki Kaisha Anticorps monoclonal permettant d'induire une apoptose
US7531643B2 (en) * 1997-09-11 2009-05-12 Chugai Seiyaku Kabushiki Kaisha Monoclonal antibody inducing apoptosis
AU2940900A (en) * 1999-03-10 2000-09-28 Chugai Seiyaku Kabushiki Kaisha Single-stranded fv inducing apoptosis
US7696325B2 (en) 1999-03-10 2010-04-13 Chugai Seiyaku Kabushiki Kaisha Polypeptide inducing apoptosis
TWI242043B (en) * 2000-03-10 2005-10-21 Chugai Pharmaceutical Co Ltd Polypeptide inducing apoptosis
AU2001246934A1 (en) * 2000-04-17 2001-10-30 Chugai Seiyaku Kabushiki Kaisha Agonist antibodies
US20040058393A1 (en) * 2000-04-17 2004-03-25 Naoshi Fukishima Agonist antibodies
EP1327681A4 (fr) 2000-10-20 2004-09-01 Chugai Pharmaceutical Co Ltd Anticorps agoniste degrade
RU2287534C2 (ru) 2000-10-20 2006-11-20 Тугаи Сейяку Кабусики Кайся Деградированное антитело, являющееся агонистом tpo
CN1308447C (zh) * 2000-10-20 2007-04-04 中外制药株式会社 低分子化的激动剂抗体
AU1091702A (en) * 2000-10-20 2002-04-29 Chugai Pharmaceutical Co Ltd Degraded tpo agonist antibody
RU2430927C2 (ru) * 2000-10-20 2011-10-10 Тугаи Сейяку Кабусики Кайся Агонистическое соединение, способное специфически узнавать и поперечно сшивать молекулу клеточной поверхности или внутриклеточную молекулу
US20050069549A1 (en) 2002-01-14 2005-03-31 William Herman Targeted ligands
US8158385B2 (en) 2002-10-11 2012-04-17 Chugai Seiyaku Kabushiki Kaisha Cell death-inducing agent
JP2004279086A (ja) 2003-03-13 2004-10-07 Konica Minolta Holdings Inc 放射線画像変換パネル及び放射線画像変換パネルの製造方法
EP1609803A4 (fr) * 2003-03-31 2006-05-24 Chugai Pharmaceutical Co Ltd Anticorps modifie dirige contre cd22 et son utilisation
US8613922B2 (en) 2003-04-24 2013-12-24 The University Of North Carolina At Chapel Hill Methods for inhibiting diabetic retinopathy with an antibody against integrin associated protein (IAP)
JP4637749B2 (ja) * 2003-11-11 2011-02-23 中外製薬株式会社 ヒト化抗ｃｄ４７抗体
TW200530269A (en) 2003-12-12 2005-09-16 Chugai Pharmaceutical Co Ltd Anti-Mpl antibodies
US20070281327A1 (en) * 2003-12-12 2007-12-06 Kiyotaka Nakano Methods of Screening for Modified Antibodies With Agonistic Activities
KR20060130606A (ko) * 2003-12-12 2006-12-19 추가이 세이야쿠 가부시키가이샤 세포사 유도제
TW200530266A (en) * 2003-12-12 2005-09-16 Chugai Pharmaceutical Co Ltd Method of reinforcing antibody activity
JP5057967B2 (ja) 2005-03-31 2012-10-24 中外製薬株式会社 ｓｃ（Ｆｖ）２構造異性体
EP1927367A4 (fr) * 2005-05-18 2009-08-12 Univ Tokushima Nouvel agent pharmaceutique a base d un anticorps anti-hla
CN101237890A (zh) 2005-06-10 2008-08-06 中外制药株式会社 含有葡甲胺的蛋白质制剂的稳定剂及其利用
JP5085322B2 (ja) 2005-06-10 2012-11-28 中外製薬株式会社 ｓｃ（Ｆｖ）２を含有する医薬組成物
WO2007033221A2 (fr) * 2005-09-13 2007-03-22 The General Hospital Corporation Methodes et compositions permettant d'inhiber des reponses immunitaires
WO2008007755A1 (fr) * 2006-07-13 2008-01-17 Chugai Seiyaku Kabushiki Kaisha inducteur de mort cellulaire
CL2008000719A1 (es) * 2007-03-12 2008-09-05 Univ Tokushima Chugai Seiyaku Agente terapeutico para cancer resistente a agentes quimioterapeuticos que comprende un anticuerpo que reconoce hla de clase i como ingrediente activo; composicion farmaceutica que comprende dicho anticuerpo; y metodo para tratar cancer resistente a
PT3056515T (pt) 2008-01-15 2019-07-19 Univ Leland Stanford Junior Métodos para manipulação da fagocitose mediada por cd47
CA2711370C (fr) 2008-01-15 2017-06-13 The Board Of Trustees Of The Leland Stanford Junior University Marqueurs des cellules souches de la leucemie myeloide aigue
WO2010017332A2 (fr) 2008-08-07 2010-02-11 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health & Human Services Radioprotecteurs ciblant la thrombospondine-1 et cd47
ME03512B (fr) * 2012-02-06 2020-04-20 Inhibrx Inc Anticorps anti-cd47 et leurs méthodes d'utilisation
MX2015007446A (es) 2012-12-12 2015-12-07 Vasculox Inc Anticuerpos terapeuticos para cd47.
US9221908B2 (en) 2012-12-12 2015-12-29 Vasculox, Inc. Therapeutic CD47 antibodies
CN116425875A (zh) 2015-09-18 2023-07-14 安驰肿瘤公司 治疗性cd47抗体
AU2017295704B2 (en) 2016-07-13 2023-07-13 President And Fellows Of Harvard College Antigen-presenting cell-mimetic scaffolds and methods for making and using the same
EP3529276A4 (fr) 2016-10-21 2020-06-17 Arch Oncology, Inc. Anticorps cd47 thérapeutiques
AR113862A1 (es) 2017-12-01 2020-06-17 Seattle Genetics Inc Anticuerpos anti-cd47 y sus usos para tratar cáncer
CN110066336B (zh) * 2019-05-12 2021-11-09 杭州科兴生物科技有限公司 抗cd47单克隆抗体、片段及其医药用途
WO2023076511A1 (fr) 2021-10-28 2023-05-04 Lyell Immunopharma, Inc. Procédés de génération de cellules
WO2024077174A1 (fr) 2022-10-05 2024-04-11 Lyell Immunopharma, Inc. Procédés de culture de cellules déficientes en nr4a
WO2025217398A1 (fr) 2024-04-10 2025-10-16 Lyell Immunopharma, Inc. Procédés de culture de cellules avec milieu de culture amélioré
WO2026006604A1 (fr) 2024-06-26 2026-01-02 Lyell Immunopharma, Inc. Substitution de cellules nourricières

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE199392T1 (de) * 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
EP0721015B1 (fr) * 1993-09-03 2004-10-27 Chugai Seiyaku Kabushiki Kaisha Anticorps monoclonal permettant d'induire une apoptose
US6719972B1 (en) * 1994-06-03 2004-04-13 Repligen Corporation Methods of inhibiting T cell proliferation or IL-2 accumulation with CTLA4- specific antibodies
US5885574A (en) * 1994-07-26 1999-03-23 Amgen Inc. Antibodies which activate an erythropoietin receptor
US5783186A (en) * 1995-12-05 1998-07-21 Amgen Inc. Antibody-induced apoptosis
AU2232597A (en) * 1996-03-06 1997-09-22 Chugai Seiyaku Kabushiki Kaisha Method of screening apoptosis inducing substances
US7531643B2 (en) * 1997-09-11 2009-05-12 Chugai Seiyaku Kabushiki Kaisha Monoclonal antibody inducing apoptosis
US7696325B2 (en) * 1999-03-10 2010-04-13 Chugai Seiyaku Kabushiki Kaisha Polypeptide inducing apoptosis

Also Published As

Publication number Publication date
RU2212413C2 (ru) 2003-09-20
AU9002898A (en) 1999-03-29
KR20040106585A (ko) 2004-12-17
PL339265A1 (en) 2000-12-04
CA2303072A1 (fr) 1999-03-18
EP1035132B1 (fr) 2008-05-14
US20030157100A1 (en) 2003-08-21
WO1999012973A1 (fr) 1999-03-18
HUP0003513A3 (en) 2004-05-28
SK3232000A3 (en) 2000-09-12
HUP0003513A2 (hu) 2001-02-28
KR20010023866A (ko) 2001-03-26
DE69839492D1 (de) 2008-06-26
ATE395362T1 (de) 2008-05-15
AU740225B2 (en) 2001-11-01
EP1035132A4 (fr) 2005-02-09
EP1035132A1 (fr) 2000-09-13
CN1276798A (zh) 2000-12-13
NO20001238D0 (no) 2000-03-09
CN1198845C (zh) 2005-04-27

Similar Documents

Publication Publication Date Title
NO20001238D0 (no) Monoklonalt antistoff som induserer apoptose
FI960567A0 (fi) Monoklonaalinen vasta-aine, joka indusoi apoptoosin
MX9603080A (es) Anticuerpos monoclonales inmuno-estimulantes.
EP1565489A4 (fr) Cible de surface cellulaire raag10 et famille d'anticorps reconnaissant cette cible
ATE318147T1 (de) Spezifische monoklonale antikörperfür die extrazelluläre domäne von protasta-spezifischem membranantigen
ATE123652T1 (de) Antigene.
TR200001253T2 (tr) Tümöre özel antijenler
ES2189873T3 (es) Agentes de imagen de resonancia magnetica para la deteccion de agentes fisiologicos.
DE69228701D1 (de) Fragmente von Prion Proteinen.
ATE464374T1 (de) Assay zum schnellen nachweis vom humanen aktivierten protein c und hochspezifischer monoklonaler antikörper dagegen
DK1167389T3 (da) Antistoffer mod SEMP1-proteinet, fremgangsmåde til fremstilling heraf samt anvendelse deraf
TW200510528A (en) Polypeptide inducing apoptosis
ATE202116T1 (de) Antikörperklassenspezifisches entstörungsreagenz
MX9706588A (es) Metodo para estimular una respuesta inmune.
ATE128738T1 (de) Verfahren zum schnellen und empfindlichen nachweis von igm-antikörpern gegen retrovirale antigene.
EA200200974A1 (ru) Моноклональные антитела к рецептору лпнп человека, их получение и применение
DE69504959D1 (de) Humanisierte monoklonale antikörper gegen humanes interleukin - 4
ATE206621T1 (de) Il-8 antagonisten zur behandlung von asthma
PT744027E (pt) Utilizacao de metodos para identificar oligopeptidos de sinal hidrofilicos
ATE160359T1 (de) Antigene regionen von tumorfreigestzten partikeln (tlp) komplexen und antikörper die sie erkennen.
EP0585364A4 (fr) Ctaa 81av78, l'antigene reconnu par l'anticorps monoclonal humain 81av78.
ES2099678B1 (es) Procedimiento para la inactivacion de virus en proteinas.
DE69132144D1 (de) Menschliche phospholipase aktivierender proteinteil
DE69533904D1 (de) Chemische Modifikation von Antikörpern und Antigenen
ES2013665A6 (es) Procedimiento para preparar un anticuerpo monoclonal humano y metodo de uso.